Leukemia therapeutics market is anticipated to grow at a significant CAGR of 6.1% during the forecast period (2024-2031). The increasing incidence of leukemia, ongoing drug development, growing awareness, and early detection of leukemia are driving the market growth. Additionally, the investment in oncology research, technological advancements, improved healthcare infrastructure, personalized medicine, and increased government funding are also contributing significantly towards the growth of the global leukemia therapeutics market. Market expansion is additionally driven by personalized medication.

Market Dynamics

Rising Incidence of Leukemia

The demand for enhanced medicines is directly driven by the rising number of leukemia cases globally, which renders the development of effective treatments imperative. The Leukemia & Lymphoma Society (LLS) Org., in 2024, projected approximately 2,001,140 new cases of cancer and 611,720 expected mortalities from the disease, in the US. Leukaemia is one of the most prevalent cancers, with an estimated 437,337 people completely diagnosed or in remission from the disease. Males are 35.9% more likely than females to be affected by leukemia.  

Increased Investment in Research and Development

Pharmaceutical companies are investing enormously in R&D to develop and enhance leukemia treatments. For instance, in January 2023, Autolus Therapeutics received approval from the FDA for its biologics license application for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory Adult B-cell acute Lymphoblastic Leukemia (ALL). The company planned to submit a marketing authorization application to the European Medicines Agency.

Market Segmentation

• Based on the drug type, the market is segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).

• Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, targeted therapy, and others ( hormonal therapy, and stem cell transplantation)

Chronic Myeloid Leukemia (CML) is projected to hold the Largest Market Share

The continuous developments in therapeutic approaches, including targeted therapy and immunotherapy, are primarily contributing to market growth. For instance, in January 2024, Novartis launched positive findings for Scemblix in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The study, part of the Phase III ASC4FIRST trial, showed that Scemblix, along with a tyrosine kinase inhibitor, produced significant results in patients. The study highlights the importance of tolerability in treating CML, a rare myeloproliferative disorder with a comparable life expectancy to the general population. 

Regional Outlook

The global leukemia therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America). 

Growing Awareness and Screening Programs in Asia-Pacific

• The regional growth is attributed to the increasing awareness programs and government initiatives leading to a rise in diagnosis and treatment rates. For instance, in March 2024, Novartis launched Asciminib, a treatment for CML, in India. The drug targets the ABL myristoyl pocket (STAMP) and is expected to be manufactured at the company's overseas facilities and imported into India.

• In April 2024, India launched its first homegrown CAR T-cell therapy for cancer patients. The therapy, developed by the Indian Institute of Technology (IIT) Bombay and Tata Memorial Centre, is expected to significantly reduce treatment costs.

Global Leukemia Therapeutics Market Growth by Region 2024-2031

North America Holds Major Market Share

Organizations and corporations are allocating significant finances to R&D to develop innovative treatments for leukemia, cultivating tactical alliances and partnerships to increase the range of available treatments and propel the market. For instance, in March 2024, Bristol Myers Squibb's Breyanzi was approved by the US FDA as the first and only CAR T cell therapy for adults with relapsed or refractory CLL or small lymphocytic lymphoma (SLL). It offers a personalized treatment option delivered as a one-time infusion, providing deep and durable responses for patients who have historically had no standard of care. The FDA granted accelerated approval based on response rate and duration of response.

• In June 2023, the Leukemia & Lymphoma Society (LLS) dosed the first patient in a clinical trial comparing a shorter combination therapy to the FDA-approved regimen in older patients with newly diagnosed AML. The trial aims to compare the effectiveness of a 14-day cycle of venetoclax and azacitidine with the FDA-approved 28-day cycle.

• In December 2023, Jaypirca was approved by Eli Lilly to treat adult patients with small lymphocytic lymphoma or chronic leukemia with lymphocytic cells that have received a minimum of two previous lines of therapy, such as BCL-2 and Bruton's Tyrosine Kinase (BTK) inhibitors. The first and only non-covalent BTK inhibitor, Jaypirca, was approved by the FDA utilizing the accelerated approval procedure. 

Market Players Outlook

*Note: Major Players Sorted in No Particular Order.

The major companies serving the leukemia therapeutics market include Bristol Myers Squibb (BMS), F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market. 

Recent Developments

• In June 2024, Eilean Therapeutics received FDA clearance for its highly potent and selective pan-FLT3/IRAK4 inhibitor, lomonitinib, allowing it to proceed with a Phase 1 clinical trial in FLT3 mutated relapsed/refractory AML. The FDA's approval allowed the trial to be initiated in the US, further expanding Eilean Therapeutics' global trial testing.

• In November 2021, Pfizer acquired Trillium Therapeutics, a clinical-stage immuno-oncology company, bringing a portfolio of biologics designed to enhance patients' immune system's ability to detect and destroy cancer cells. Trillium's lead molecules, TTI-622 and TTI-621, block the SIRP?-CD47 axis, a key immune checkpoint in hematological malignancies.

The Report Covers

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global leukemia therapeutics market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.